Comparison of the efficacy of salbutamol sustained release capsule and bambuterol tablet in asthma

程齐俭,黄绍光,许以平,林建海,何礼贤,陈小东
DOI: https://doi.org/10.3969/j.issn.1007-4406.2003.06.001
2003-01-01
Abstract:AIM: To compare efficacy and safety between salbutamol sustained release capsule and bambuteroltablet in patients with chronic reversible obstructive airway disease. METHODS: One hundred and forty-four asthmatic patients were randomly divided into salbutamol sustained release capsule group with 77 patients and bambuterol group with 67, respectively. These patients received salbutamol sustained release capsule 8 mg, po, bid; or bambuterol 20 mg, po, qd for 14 d. For all patients,nocturnal and daytime symptoms,the use of inhaled β2 adrenoreceptor agonist, value of FEV1 and the daily variance rate of PEFR were recorded. RETS: After treated by salbutamol sustained release capsule for 2 wk, nocturnal and daytime symptoms were significantly improved, inhaled β2 adrenoreceptor agonist use was reduced, the integrated effective rate of nocturnal and daytime symptoms was 57% and 60%, respectively, value of FEV1 was markedly enhanced and the daily variance rate of PEFR was evidently reduced as compared with baseline, the efficacy was similar with that of bambuterol. Asthma patients showed good tolerance to these two drugs. CONCLUSION: Salbutamol sustained release capsule is suitable for clinical control of persistent asthma patients, its efficacy and safety is similar with bambuterol.
What problem does this paper attempt to address?